EV Manufacturing Diligence Atlas
Extracellular vesicle therapeutics remain scientifically plausible but commercially hard. EV manufacturing is no longer impossible, but it is a CMC-heavy development problem with unclear comparability standards and limited late-stage clinical validation.
Citations support hypotheses; expert feedback updates confidence — not endorsement.
Defined source cell & cell bank
Master/working cell bank with controlled production state.
View process map →Mechanism-linked potency assay
Fit-for-purpose potency tied to intended mechanism in the target indication.
View process map →Scalable closed manufacturing
Closed, reproducible process with defined isolation and release strategy.
View process map →Indication with delivery advantage
Local/targeted delivery or clear advantage vs cells, proteins, LNPs, or gene therapy.
View process map →CMC risk landscape
Top risks
Full process map →Potency assay ambiguity
Weak potency assays are a regulatory and investor warning sign
View linked process steps →Cell source variability
Product quality begins with cell banking and culture control
View linked process steps →Isolation method bias
Process defines the product
View linked process steps →Heterogeneity
Identity and purity are hard to prove
View linked process steps →Culture-condition sensitivity
Same cells do not guarantee same drug
View linked process steps →